An antibody therapy against a key inflammatory molecule involved in migraines reduces the number of headaches that chronic migraine patients experience per month in a phase III trial
A new study of fremanezumab, an immunotherapy that counteracts one of the molecules released during migraine, was found successful in reducing the number of days that chronic migraine sufferers experienced headaches. The results of the phase III clinical trial were published November 29, 2017 in the New England Journal of Medicine.
The World Health Organization estimates that between 127 and 300 million people around the world experience chronic migraine, defined as 15 or more headaches per month for at least three months. The disease can be debilitating and although a number of interventions exist, many only work for a certain time before they fail to prevent or relieve pain.
“This therapeutic approach offers new hope for people whose migraines cannot be treated with existing medicine,” says Stephen D. Silberstein, M.D., principal investigator of the HALO CM trial, Professor of Neurology and Director of the Jefferson Headache Center at the Vicki & Jack Farber Institute for Neuroscience at Thomas Jefferson University Hospital. “Our worldwide effort to evaluate this novel therapeutic approach has shown positive results and was safe in patients.”
Fremanezumab, a monocolonal antibody developed by Teva Pharmaceuticals, is a biological agent that binds to and blocks the action of a migraine-associated protein called calcitonin gene-related peptide (CGRP). Mounting evidence of its importance in migraines has made CGRP a focal point of research and drug development. The peptide is released at high levels during migraine in response to inflammation, and triggers a cascade effect that stimulates more CGRP release. This results in increasing sensitivity of the brain to pain. By blocking this peptide, doctors hope to break the cycle of increasing inflammation and increased pain sensitivity that contributes to migraine headaches.
Researchers from 132 sites across nine countries enrolled 1130 patients and randomly assigned them to one of three groups: one that received quarterly treatments, a group that received one treatment per month, and one that received placebo injections. The trial lasted for 16 weeks, with a 12-week treatment window.
The results of the trial show that treatment with fremanezumab reduced the number of days patients experience headache by an average of 4.3 days with quarterly treatment and 4.6 days with monthly treatment. “We saw some patients with 100 percent reduction in migraine, others with 75 percent reduction,” says Dr. Silberstein. The level of response varied between patients.
The researchers also looked at how well the therapy worked relative to each patient’s headache burden. They calculated the percent of patients who had more than a 50 percent reduction in the number of days they experienced either a severe or moderate headache per month. Using this measure, the researchers saw that 37.6 percent of patients on the monthly regimen, and 40.8 percent on the quarterly regimen had at least a 50 percent reduction in the number of moderate headaches per month, compared to 18.1 percent in the placebo group.
The therapy had a favorable safety profile with the most common adverse event reported as irritation at injection site, which was reported in the placebo group as well.
“If approved, this treatment would provide physicians with an important new tool to help prevent migraine, reduce a patient’s migraine load, and potentially help patients return to normal” says Dr. Silberstein.
The Latest on: Migraines
[google_news title=”” keyword=”migraines” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Do Taurine Supplements Reduce MSG-Induced Migraines? Some Say Yes, But the Jury's Still Outon February 3, 2023 at 4:29 am
Some doctors believe that MSG is an excitotoxin, which is a substance that can overstimulate neurons in the brain, causing them to become exhausted. In rare cases, this can create inflammation and ...
- Get Headaches? Try Eating More of This Nutrienton February 2, 2023 at 2:16 pm
This might have been annoying advice when you were young...but new research shows there's actual wisdom to it.
- YOUR HEALTH: Migraine warning signson February 2, 2023 at 4:13 am
When a migraine happens, it can sideline you from work, family affairs and daily life. There are some early warning signs you should know and new medications on the horizon. The throbbing and pounding ...
- He believes a COVID vaccine caused his searing pain. Now, he's on a quest for answers.on February 2, 2023 at 1:01 am
About 10,000 New Yorkers have reported adverse reactions to COVID vaccines. Here's what to know about legitimate cases amid rampant misinformation.
- Migraine study: Boston researchers find migraines tied to higher risk for pregnancy complicationson January 31, 2023 at 4:37 pm
Women suffering from migraines could be at an increased risk for pregnancy complications, according to Boston researchers in a new study.
- My little boy saved my life after ‘migraines’ turned out to be killer diseaseon January 30, 2023 at 4:40 am
A MUM has claimed her baby boy saved her life after doctors discovered a fast-growing brain tumour – just weeks after she had given birth. Abi Naylor started to experience excruciating ...
- New mum’s 'excruciating migraines' turned out to be a fast-growing brain tumouron January 30, 2023 at 4:05 am
Abi Naylor had only just given birth to her son when she began suffering from painful migraines, then within days could 'barely walk or see'.
- New NHS drug will help thousands with migraineson January 26, 2023 at 12:27 am
Migraines are common, affecting around one in every five women and around one in every 15 men Thousands of people who suffer from migraines could benefit from a drug that has been approved on the NHS.
- Migraines are very common in Australia. So why are they under-diagnosed and under-treated?on January 23, 2023 at 1:58 pm
Experts say there are many reasons why medical practitioners struggle to treat migraine but there are ways to address it.
- 33 Best Magnesium Supplements For Migraineson January 22, 2023 at 10:53 pm
The Adivasis don’t milch cows for milk, but leave it for their calves to grow stronger to help them in cultivating their fields. They celebrate both cow and buffalo as their trusted friends.
via Google News and Bing News